Photo from wikipedia
Key Points Question Is initiation of angiotensin II receptor blockers (ARBs), compared with angiotensin-converting enzyme inhibitors (ACEIs), associated with a reduced risk of cognitive impairment, after controlling for potential pretreatment… Click to show full abstract
Key Points Question Is initiation of angiotensin II receptor blockers (ARBs), compared with angiotensin-converting enzyme inhibitors (ACEIs), associated with a reduced risk of cognitive impairment, after controlling for potential pretreatment confounders? Findings This active-comparator, new-user design cohort study identified 2040 new users of ACEIs/ARBs from the Systolic Blood Pressure Intervention Trial (SPRINT). The overall risk of cognitive impairment was not appreciably different between new users of an ARB vs ACEI. Meaning The findings of this study suggest that pragmatic trials reflective of blood pressure management outside the clinical trial setting are warranted to further elucidate cognitive outcomes with ARBs vs ACEIs initiation.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!